<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2012211494
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        FORTA-Z 1 g powder for solution for injection
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CEFTAZIDIME
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        g
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Parenteral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        powder for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        38.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hikma Farmaceutica" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hikma Farmaceutica
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01DD02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Forta-Z is an antibiotic used in adults and children (including newborn babies). It works by killing bacteria that cause infections. It belongs to a group of medicines called cephalosporins.</p><p>Forta-Z is used to treat severe bacterial infections of:</p><ul><li>The lungs or chest.</li><li>The lungs and bronchi in patients suffering from cystic fibrosis.</li><li>The brain (meningitis).</li><li>The ear.</li><li>The urinary tract.</li><li>The skin and soft tissues.</li><li>The abdomen and abdominal wall (peritonitis).</li><li>The bones and joints.</li></ul><p>Forta-Z can also be used:</p><ul><li>To prevent infections during prostate surgery in men.</li><li>To treat patients with low white blood cell counts (neutropenia) who have a fever due to a bacterial infection.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Forta-Z</strong></p><ul><li>If you are allergic to ceftazidime or any of the other ingredients of this medicine (listed in section 6).</li><li>If you have had a severe allergic reaction to any other antibiotic (penicillins, monobactams and carbapenems) as you may also be allergic to Forta-Z.</li></ul><p>Tell your doctor before you start on Forta-Z if you think that this applies to you. You must not be given Forta-Z.</p><p><strong>Warnings and precautions</strong><br />You must look out for certain symptoms such as allergic reactions, nervous system disorders and gastrointestinal disorders such as diarrhoea while you are being given Forta-Z. This will reduce the risk of possible problems.</p><p>See (&lsquo;Conditions you need to look out for&rsquo;) in section 4. If you have had an allergic reaction to other antibiotics you may also be allergic to Forta-Z.</p><p><strong>If you need a blood or urine test</strong><br />Forta-Z can affect the results of urine tests for sugar and a blood test known as the Coombs test. If you are having tests: Tell the person taking the sample that you have been given Forta-Z.</p><p><strong>Other medicines and Forta-Z</strong><br />Tell your doctor if you are taking, have recently taken or might take any other medicines. This includes medicines you can obtain without a prescription.</p><p>You shouldn&rsquo;t be given Forta-Z without talking to your doctor if you are also taking:</p><ul><li>An antibiotic called chloramphenicol.</li><li>A type of antibiotic called aminoglycosides e.g. gentamicin, tobramycin.</li><li>Water tablets called furosemide.</li></ul><p>Tell your doctor if this applies to you.</p><p><strong>Pregnancy and breast-feeding</strong><br />Ask your doctor for advice before you are given Forta-Z:</p><ul><li>If you are pregnant, think you might be pregnant or are planning to become pregnant.</li><li>If you are breast-feeding.</li></ul><p>Your doctor will consider the benefit of treating you with Forta-Z against the risk to your baby.</p><p><strong>Driving and using machines</strong><br />Ceftazidime can cause side effects that affect your ability to drive, such as dizziness. Don&rsquo;t drive or use machines unless you are sure you&rsquo;re not affected.</p><p><strong>Forta-Z contains sodium</strong><br />Forta-Z contains sodium. Each vial of Forta-Z 1 g Powder for Solution for Injection/Infusion contains 84.19 mg sodium (main component of cooking/table salt). This is equivalent to 4.21% of the recommended maximum daily dietary intake of sodium for an adult.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Forta-Z is usually given by a doctor or nurse. &nbsp;</p><p>Forta-Z 1 g Powder for Solution for Injection/Infusion can be given as a drip (intravenous infusion) or as an injection directly into a vein or into a muscle. &nbsp;</p><p>Forta-Z is made up by the doctor, pharmacist or nurse using water for injection or a suitable infusion fluid.</p><p><strong>The recommended dose</strong><br />The correct dose of Forta-Z for you will be decided by your doctor and depends on: the severity and type of infection; whether you are on any other antibiotics; your weight and age; how well your kidneys are working.</p><p><strong>&nbsp;Newborn babies (0-2 months)</strong><br />For every 1 kg the baby weighs, they&rsquo;ll be given 25 to 60 mg Forta-Z per day divided in two doses.</p><p><strong>Babies (over 2 months) and children who weigh less than 40 kg</strong><br />For every 1 kg the baby or child weighs, they&rsquo;ll be given 100 to 150 mg of Forta-Z per day divided in three doses. Maximum 6 g per day.</p><p><strong>Adults and adolescents who weigh 40 kg or more</strong><br />1 to 2 g of Forta-Z three times daily. Maximum of 9 g per day.</p><p><strong>Patients over 65</strong><br />The daily dose should not normally exceed 3 g per day, especially if you are over 80 years of age.</p><p><strong>Patients with kidney problems</strong><br />You may be given a different dose to the usual dose. The doctor or nurse will decide how much Forta-Z you will need, depending on the severity of the kidney disease. Your doctor will check you closely and you may have more regular kidney function tests.</p><p><strong>If you use more Forta-Z than you should</strong><br />If you accidentally use more than your prescribed dose, contact your doctor or nearest hospital straight away.</p><p><strong>If you forget to use Forta-Z</strong><br />If you miss an injection, you should have it as soon as possible. Don&rsquo;t take a double dose (two injections at the same time) to make up for a missed dose just take your next dose at the usual time.</p><p><strong>&nbsp;If you stop using Forta-Z</strong><br />Don&rsquo;t stop taking Forta-Z unless your doctor tells you to.</p><p>If you have any further questions on the use of this medicine ask your doctor or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Conditions you need to look out for</strong><br />The following serious side effects have occurred in a small number of people but their exact frequency is unknown:</p><ul><li>Severe allergic reaction. Signs include raised and itchy rash, swelling, sometimes of the face or mouth causing difficulty in breathing.</li><li>Skin rash, which may blister, and looks like small targets (central dark spot surrounded by a paler area, with a dark ring around the edge).</li><li>A widespread rash with blisters and peeling skin. (These may be signs of Stevens-Johnson syndrome or toxic epidermal necrolysis).</li><li>Nervous system disorders: tremors, fits and, in some cases coma. These have occurred in people when the dose they are given is too high, particularly in people with kidney disease.</li><li>There have been rare reports of severe hypersensitivity reactions with severe rash, which may be accompanied by fever, fatigue, swelling of the face or lymph glands, increase of eosinophils (type of white blood cells), effects on liver, kidney or lung (a reaction called DRESS).</li></ul><p>Contact a doctor or nurse immediately if you get any of these symptoms.</p><p><strong>Common side effects</strong><br />These may affect up to 1 in 10 people:</p><ul><li>Diarrhoea.</li><li>Swelling and redness along a vein.</li><li>Red raised skin rash which may be itchiness.</li><li>Pain, burning, swelling or inflammation at the injection site.</li></ul><p>Tell your doctor<strong> </strong>if any of these are troubling you.</p><p>Common side effects that may show up in blood tests:</p><ul><li>An increase in a type of white blood cell (eosinophilia).</li><li>An increase in the number of cells that help the blood to clot.</li><li>An increase in liver enzymes.</li></ul><p><strong>Uncommon side effects</strong><br />These may affect up to 1 in 100 people:</p><ul><li>Inflammation of the gut which can cause pain, or diarrhoea which may contain blood.</li><li>Thrush (fungal infections in the mouth or vagina).</li><li>Headache.</li><li>Dizziness.</li><li>Stomach ache.</li><li>Feeling sick or being sick.</li><li>Fever and chills.</li></ul><p>Tell your doctor if you get any of these.</p><p>Uncommon side effects that may show up in blood tests:</p><ul><li>A decrease in the number of white blood cells.</li><li>A decrease in the number of blood platelets (cells that help the blood to clot).</li><li>An increase in the level of urea, urea nitrogen or serum creatinine in the blood.</li></ul><p><strong>Very rare side effects</strong><br />These may affect up to 1 in 10,000 people:</p><ul><li>Inflammation or failure of the kidneys.</li></ul><p><strong>Other side effects</strong><br />Other side effects have occurred in a small number of people but their exact frequency is unknown:</p><ul><li>Pins and needles.</li><li>Unpleasant taste in the mouth.</li><li>Yellowing of the whites of the eyes or skin.</li></ul><p>Other side effects that may show up in blood tests:</p><ul><li>Red blood cells destroyed too quickly.</li><li>An increase in a certain type of white blood cells.</li><li>Severe decrease in the number of white blood cells.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 30&deg;C.</p><p>Store in the original package to protect from light.</p><p>Reconstituted and diluted solution: The doctor, pharmacist or nurse will make up your medicine in water for injection or compatible fluids. Once made up, this medicine should be used within 24 hours when stored in the refrigerator at (2-8&deg;C).</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any visible signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is ceftazidime pentahydrate.</p><p>Each vial of Forta-Z 1 g Powder for Solution for Injection/Infusion contains ceftazidime pentahydrate equivalent to 1 g ceftazidime.</p><p>The other ingredient is sodium carbonate.&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Forta-Z 1 g Powder for Solution for Injection/Infusion is a white to pale yellow powder in 50 ml type II clear moulded glass vials sealed with bromobutyl rubber stoppers and aluminum caps.

Your doctor, pharmacist or nurse will make the injection or infusion up with water for injection or a suitable infusion fluid. When made up, Forta-Z varies in colour from light yellow to amber. This is perfectly normal.

Pack size: 1 Vial.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong><br />Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. Box 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: SAPV@hikma.com</p><p><strong>Manufacturer</strong><br />Hikma Farmaceutica (Portugal), S.A.<br />Estrada do Rio Da M&oacute;,<br />n.&deg;8, 8A e 8B, Ferven&ccedil;a<br />2705-906 Terrugem<br />Sintra, Portugal<br />Tel: + (351-2) 19608410<br />Fax: + (351-2) 19615102</p><p><strong>Reporting of side effects</strong><br />If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 02/2024; version number SA3.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">فورتا-زي هو مضاد حيوي يستخدم لدى لبالغين والأطفال (بما في ذلك الأطفال حديثي الولادة). وهو يعمل عن طريق قتل البكتيريا التي تسبب العدوى. وهو ينتمي إلى مجموعة من الأدوية تسمى السيفالوسبورينات.</p><p dir="RTL">يستخدم فورتا-زي لعلاج العدوى البكتيرية الشديدة التي تصيب:</p><ul dir="rtl"><li>الرئتين أو الصدر.</li><li>الرئتين والشعب الهوائية في المرضى الذين يعانون من التليف الكيسي.</li><li>الدماغ (التهاب السحايا).</li><li>الأذن.</li><li>المسالك البولية.</li><li>الجلد والأنسجة الرخوة.</li><li>البطن وجدار البطن (التهاب&nbsp;الصِّفاق).</li><li>العظام والمفاصل.</li></ul><p dir="RTL">يمكن استخدام فورتا-زي أيضاً:</p><ul dir="rtl"><li>لمنع العدوى أثناء جراحة البروستات في الرجال.</li><li>لعلاج المرضى الذين يعانون من انخفاض عدد خلايا الدم البيضاء (قلة العدلات) ويعانون من حمى بسبب عدوى بكتيرية.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم </strong><strong>فورتا-زي</strong></p><ul dir="rtl"><li>إذا كنت تعاني من حساسيًة لسيفتازيديم أو لأي من المواد المستخدمة في تركيبة هذا الدواء (المذكورة في قسم 6).</li><li>إذا كنت قد عانيت من تفاعل تحسسي شديد لأي مضاد حيوي آخر (مثل البنسلينات، المونوباكتامات، والكاربابينيمات) حيث أنه من الممكن أيضاً أن يكون لديك حساسية لفورتا-زي.</li></ul><p dir="RTL">أخبر طبيبك قبل البدء بتناول فورتا-زي إذا كنت تعتقد أنه ينطبق عليك أي مما سبق. يجب ألا يتم إعطاؤك فورتا-زي.</p><p dir="RTL"><strong>الاحتياطات والتحذيرات</strong><br />يجب أن تنتبه إلى ظهور أعراض معينة مثل ردود فعل تحسسية، اضطرابات الجهاز العصبي واضطرابات الجهاز الهضمي مثل الإسهال أثناء إعطاؤك فورتا-زي. إن هذا سوف يقلل من خطورة حدوث المشاكل المحتملة.</p><p dir="RTL">انظر (&quot;الحالات التي تتطلب انتباهك&quot;) في القسم 4. إذا كنت قد عانيت من تفاعل تحسسي لأي مضاد حيوي آخر فإنه من الممكن أيضاً أن يكون لديك حساسية لفورتا-زي.</p><p dir="RTL"><strong>إذا كنت بحاجة لإجراء فحص دم أو بول&nbsp;</strong><br />فورتا-زي قد يؤثر على نتائج السكر في فحوصات البول وعلى فحص الدم المعروف بفحص كومبس. إذا كانت لديك فحوصات: أخبر الشخص الذي يأخذ العينة بأنه تم إعطاؤك فورتا-زي.</p><p dir="RTL"><strong>الأدوية الأخرى وفورتا-زي&nbsp;</strong><br />أخبر طبيبك إذا كنت تأخذ، أخذت مؤخراً أو قد تأخذ أية أدوية أخرى. يتضمن ذلك الأدوية التي تم الحصول عليها بدون وصفة طبية.</p><p dir="RTL">يجب ألا تأخذ فورتا-زي قبل التحدث مع طبيبك إذا كنت تأخذ أيضاً:</p><ul dir="rtl"><li>مضاد حيوي يسمى كلورامفينيكول.</li><li>نوع من المضادات الحيوية تسمى الأمينوغليكوزيدات، على سبيل المثال جانتاميسين، وتوبراميسين.</li><li>مدر البول المسمى فوروسيميد.</li></ul><p dir="RTL">أخبر طبيبك إذا كان هذا ينطبق عليك.</p><p dir="RTL"><strong>الحمل والرضاعة&nbsp;</strong><br />يرجى استشارة طبيبك قبل أن يتم إعطاؤك فورتا-زي:</p><ul dir="rtl"><li>إذا كنت حاملاً، تعتقدين أنك حاملاً أو تخططين للحمل.</li><li>إذا كنت مرضعًا.</li></ul><p dir="RTL">سوف يقوم طبيبك بتقييم الفوائد من علاجك باستخدام فورتا-زي مقابل الخطر على طفلك.</p><p dir="RTL"><strong>القيادة واستخدام الآلات&nbsp;</strong><br />يمكن أن يسبب سيفتازيديم حدوث آثاراً جانبيةً تؤثر على قدرتك على القيادة، مثل الدوخة. لا تقم بالقيادة أو استخدام الآلات إلا إذا كنت متأكداً أنك لا تعاني من هذه الآثار.</p><p dir="RTL"><strong>يحتوي فورتا-زي على الصوديوم&nbsp;</strong><br />يحتوي فورتا-زي على الصوديوم. تحتوي كل زجاجة من فورتا-زي 1 غم مسحوق للحل للحقن/للتسريب على 84,19 ملغم صوديوم (المكون الرئيسي للطبخ/ملح الطعام). هذا يكافئ 4,21% من الحد الأقصى الموصى به من الحصة الغذائية اليومية من الصوديوم للبالغين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتم إعطاء فورتا-زي عادةً من قبل الطبيب أو الممرض.</p><p dir="RTL">يمكن إعطاء فورتا-زي 1 غم مسحوق للحل للحقن/للتسريب عن طريق التنقيط (التسريب الوريدي) أو عن طريق الحقن مباشرةً في الوريد أو داخل العضل.</p><p dir="RTL">يتم تحضير فورتا-زي بواسطة الطبيب، الصيدلي أو الممرض بإستخدام ماء معد للحقن أو سائل التسريب المناسب.</p><p dir="RTL"><strong>الجرعة الموصى بها&nbsp;</strong><br />سيقرر طبيبك الجرعة الصحيحة لك من فورتا-زي وذلك يعتمد على: شدة ونوع العدوى؛ إذا ما كنت تتناول أي مضادات حيوية أخرى؛ وزنك وعمرك؛ مدى فاعلية عمل كليتيك.</p><p dir="RTL"><strong>حديثي الولادة (0 إلى شهرين)&nbsp;</strong><br />لكل 1 كغم من وزن الطفل، سوف يتم إعطاؤهم 25 إلى 60 ملغم من فورتا-زي في اليوم مقسمة على جرعتين.</p><p dir="RTL"><strong>الرضع (الأكبر من شهرين) والأطفال الذين يزنون أقل من 40 كغم &nbsp;</strong><br />لكل 1 كغم من وزن الرضيع أو الطفل، سوف يتم إعطاؤهم 100 إلى 150 ملغم من فورتا-زي في اليوم مقسمة على ثلاث جرعات. 6 غم في اليوم كحد أقصى.</p><p dir="RTL"><strong>البالغين والمراهقون الذين يزنون 40 كغم أو أكثر&nbsp;</strong><br />1 إلى 2 غم من فورتا-زي ثلاث مرات يومياً. 9 غم في اليوم كحد أقصى.</p><p dir="RTL"><strong>المرضى الذين تتجاوز أعمارهم 65 عاماً&nbsp;</strong><br />لاينبغي أن تتجاوز الجرعة اليومية عادةً 3 غم في اليوم، خاصة إذا كنت تزيد عن 80 عاماً.</p><p dir="RTL"><strong>&nbsp;المرضى الذين يعانون من مشاكل في الكلى&nbsp;</strong><br />قد يتم إعطاؤك جرعة مختلفة عن الجرعة العادية. سوف يقرر الطبيب أو الممرض كمية فورتا-زي التي تحتاجها، اعتماداً على شدة مرض الكلى. سيقوم طبيبك بفحصك عن كثب وقد تكون لديك فحوصات وظائف كلى بشكل منتظم أكثر.</p><p dir="RTL"><strong>إذا استخدمت فورتا-زي أكثر من اللازم&nbsp;</strong><br />اتصل بطبيبك أو بأقرب مستشفى على الفور، إذا قمت باستخدام جرعة أكبر من الجرعة المحددة عن طريق الخطأ.</p><p dir="RTL"><strong>إذا نسيت استخدام فورتا-زي&nbsp;</strong><br />إذا فوّتّ حقنة، يجب أن تعطى الجرعة في أقرب وقت ممكن. لا تقم بأخذ جرعة مضاعفة (حقنتين في الوقت نفسه) لتعويض الجرعة المنسية خذ الجرعة التالية في الوقت المعتاد.</p><p dir="RTL"><strong>إذا توقفت عن استخدام فورتا-زي&nbsp;</strong><br />لا تتوقف عن أخذ فورتا-زي ما لم يخبرك الطبيب بذلك.</p><p dir="RTL">إذا كان لديك أي أسئلة إضافية حول استخدام هذا الدواء اسأل الطبيب أو الممرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن لهذا الدواء أن يسبب أعراضاً جانبية، إلا أنها قد لا تحدث لدى جميع مستخدمي هذا الدواء.</p><p dir="RTL"><u>&nbsp;</u><strong>الحالات التي تتطلب انتباهك</strong><br />حدثت الآثار الجانبية الخطيرة التالية لدى عدد قليل من الأشخاص ولكنها غير معروفة التكرار على وجه الدقة:</p><ul dir="rtl"><li>تفاعل تحسسي شديد. تشمل علامات طفح جلدي بارز يرافقه حكة، تورم، أحيانا في الوجه أو الفم مما يسبب صعوبة في التنفس.</li><li>طفح جلدي، يمكن أن يكوًن بثور، والتي تظهر على شكل أهداف صغيرة (بقع غامقة في المركز محاطة بمنطقة شاحبة اللون، ويحيطها حلقة داكنة اللون).</li><li>طفح جلدي منتشر على نطاق واسع يرافقه ظهور بثور وتقشر في الجلد. (قد تكون هذه من علامات متلازمة ستيفنز جونسون أو تقشر الأنسجة المتموّتة البشروية التسممي).</li><li>اضطرابات الجهاز العصبي: رعاش، نوبات، وفي بعض الحالات غيبوبة. حدثت هذه الآثار لدى الناس الذين تم إعطاؤهم جرعة مرتفعة للغاية، وخاصة الأشخاص الذين يعانون من اختلالات في وظائف الكلى.</li><li>تم الابلاغ بشكل نادر عن فرط الحساسية الشديدة مع طفح جلدي شديد، والذي قد يرافقه الحمى، التعب، تورم في الوجه أو الغدد الليمفاوية، &nbsp;زيادة في اليوزينيات (نوع من خلايا الدم البيضاء)، آثار في الكبد، الكلى أو الرئة (تفاعل يسمى التفاعل الدوائي مع اليُوزينِيَّات والأعراض الجهازية).</li></ul><p dir="RTL">اتصل بالطبيب أو الممرض على الفور إذا ظهرت لديك أي من هذه الأعراض.</p><p dir="RTL"><strong>الآثار الجانبية الشائعة</strong><br />قد تؤثر على شخص من كل 10 أشخاص:</p><ul dir="rtl"><li>الإسهال.</li><li>التورم والاحمرار على امتداد الوريد.</li><li>طفح جلدي بارز مع احمرار قد يرافقه حكة.</li><li>ألم، حرقة، تورم أو التهاب في موضع الحقن.</li></ul><p dir="RTL">أخبر طبيبك إذا كانت أي من هذه الآثار تزعجك.</p><p dir="RTL">الآثار الجانبية الشائعة التي قد تظهر في فحوصات الدم:</p><ul dir="rtl"><li>زيادة في نوع من خلايا الدم البيضاء (اليوزينيات).</li><li>زيادة في عدد الخلايا التي تساعد على تجلط الدم.</li><li>زيادة في أنزيمات الكبد.</li></ul><p dir="RTL"><strong>الآثار الجانبية غير الشائعة</strong><br />تؤثر على شخص من كل 100 شخص:</p><ul dir="rtl"><li>التهاب الأمعاء الذي يمكن أن يسبب الألم، أو الإسهال الذي قد يحتوي على الدم.</li><li>سلاق (التهابات فطرية في الفم أو المهبل).</li><li>صداع.</li><li>دوخة.</li><li>ألم في المعدة.</li><li>الغثيان أو القيء.</li><li>حمى و قشعريرة.</li></ul><p dir="RTL">أخبر طبيبك إذا ظهرت لديك أي من هذه الأعراض.</p><p dir="RTL">الآثار الجانبية غير الشائعة التي قد تظهر في فحوصات الدم:</p><ul dir="rtl"><li>انخفاض في عدد خلايا الدم البيضاء.</li><li>انخفاض في عدد الصفائح الدموية (الخلايا التي تساعد على تجلط الدم).</li><li>زيادة في مستوى اليوريا، نيتروجين اليوريا أو الكرياتينين في مصل الدم.</li></ul><p dir="RTL"><strong>آثار جانبية نادرة جداً</strong><br />تؤثر على شخص من كل 10000 شخص:</p><ul dir="rtl"><li>التهاب الكلى أو الفشل الكلوي.</li></ul><p dir="RTL"><strong>الآثار الجانبية الأخرى&nbsp;</strong><br />حدثت آثار جانبية أخرى لدى عدد قليل من الناس لكنها غير معروفة التكرار على وجه الدقة:</p><ul dir="rtl"><li>وخز كالإبر والدبابيس.</li><li>طعم غير مرغوب في الفم.</li><li>اصفرار بياض العينين أو الجلد.</li></ul><p dir="RTL">الآثار الجانبية الأخرى التي قد تظهر في فحوصات الدم:</p><ul dir="rtl"><li>تكسر خلايا الدم الحمراء بسرعة كبيرة جداً.</li><li>زيادة في نوع معين من خلايا الدم البيضاء.</li><li>انخفاض شديد في عدد خلايا الدم البيضاء.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ عند درجة حرارة أقل من 30˚ مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية للحماية من الضوء.</p><p dir="RTL">المحلول الذي تم حله وتخفيفه: سيقوم الطبيب، الصيدلي أو الممرض بحل دوائك باستخدام الماء المعد للحقن أو السوائل المتوافقة. بمجرد تحضير الدواء، يجب استخدامه خلال 24 ساعة عند حفظه داخل الثلاجة (2-8&deg; مئوية).</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على المذكور على العبوة الخارجية بعد &quot;EXP&quot;.&rlm;‫يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت علامات تلف واضحة عليه.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعّالة هي سيفتازيديم خماسي الماء.</p><p dir="RTL">تحتوي كل زجاجة من فورتا-زي 1 غم مسحوق للحل للحقن/للتسريب على سيفتازيديم خماسي الماء يكافئ 1 غم سيفتازيديم.</p><p dir="RTL">المادة الأخرى المستخدمة في التركيبة التصنيعية هي كربونات الصوديوم.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">فورتا-زي 1 غم مسحوق للحل للحقن/للتسريب هو مسحوق أبيض إلى أصفر باهت في زجاجات شفافة مقولبة من النوع رقم اثنان بحجم 50 مللتر مغلقة بسدادات مطاطية من البروموبيوتيل وأغطية من الألمنيوم.</p><p dir="RTL">سيقوم الطبيب، الصيدلي أو الممرض بتحضير دواء الحقن أو التسريب باستخدام الماء المعد للحقن أو سائل التسريب المناسب. عند تحضير الدواء، يختلف لون فورتا-زي من الأصفر الفاتح إلى الكهرماني. وهذا أمر طبيعي تماماً.</p><p dir="RTL">حجم العبوة: زجاجة واحدة.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق</strong><br />شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 8107023 (11-966) +، 2142472 (11-966) +&nbsp;<br />فاكس: 2078170 (11-966)&nbsp;+<br />البريد الإلكتروني: SAPV@hikma.com</p><p dir="RTL"><strong>&nbsp;الشركة المصنعة</strong><br />شركة أدوية الحكمة (البرتغال)، المساهمة العامة المحدودة<br />إسترادا دو ريو دا مو،<br /><img src="data:image/png;base64,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" alt="" width="136" height="15" vspace="0" hspace="0" border="0" style="width:136px;height:15px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /><br />2705-906 تيروجيم<br />سنترا، البرتغال<br />هاتف: 19608410 (2-351) +<br />فاكس: 19615102 (2-351) +</p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية</strong><br />تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; المملكة العربية السعودية</p><p dir="RTL">المركز الوطني للتيقظ الدوائي<br />مركز الاتصال الموحد: 19999<br />البريد الإلكتروني: npc.drug@sfda.gov.sa<br />الموقع الإلكتروني: &nbsp;https://ade.sfda.gov.sa</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; دول الخليج العربي الأخرى</p><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 02/2024؛ رقم النسخة SA3.0.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Forta-Z 1 g Powder for Solution for Injection/Infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains ceftazidime pentahydrate equivalent to 1 g ceftazidime.

Excipient with known effect: Sodium. 

For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for Solution for Injection/Infusion.

White to pale yellow powder.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Forta-Z is indicated for the treatment of the infections listed below in adults and&nbsp;children including neonates (from birth).</p><ul><li>Nosocomial pneumonia</li><li>Broncho-pulmonary infections in cystic fibrosis</li><li>Bacterial meningitis</li><li>Chronic suppurative otitis media</li><li>Malignant otitis externa</li><li>Complicated urinary tract infections</li><li>Complicated skin and soft tissue infections</li><li>Complicated intra-abdominal infections</li><li>Bone and joint infections</li><li>Peritonitis associated with dialysis in patients on CAPD.</li></ul><p>Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.</p><p>Ceftazidime may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.</p><p>Ceftazidime may be used in the peri-operative prophylaxis of urinary tract infections for patients undergoing transurethral resection of the prostate (TURP).</p><p>The selection of ceftazidime should take into account its antibacterial spectrum, which is mainly restricted to aerobic Gram negative bacteria (see sections 4.4 and 5.1).</p><p>Ceftazidime should be co-administered with other antibacterial agents whenever the possible range of causative bacteria would not fall within its spectrum of activity.</p><p>Consideration should be given to official guidelines on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><u>Table 1: Adults and children &ge; 40 kg</u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><em>Intermittent Administration</em></p></td></tr><tr><td style="vertical-align:top"><p>Infection</p></td><td style="vertical-align:top"><p>Dose to be administered</p></td></tr><tr><td style="vertical-align:top"><p>Broncho-pulmonary infections in cystic fibrosis</p></td><td style="vertical-align:top"><p>100 to 150 mg/kg/day every 8 h, maximum 9 g per day<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Febrile neutropenia</p></td><td rowspan="4" style="vertical-align:top"><p>&nbsp;</p><p>2 g every 8 h</p></td></tr><tr><td style="vertical-align:top"><p>Nosocomial pneumonia</p></td></tr><tr><td style="vertical-align:top"><p>Bacterial meningitis</p></td></tr><tr><td style="vertical-align:top"><p>Bacteraemia*</p></td></tr><tr><td style="vertical-align:top"><p>Bone and joint infections</p></td><td rowspan="4" style="vertical-align:top"><p>&nbsp;</p><p>1-2 g every 8 h</p></td></tr><tr><td style="vertical-align:top"><p>Complicated skin and soft tissue infections</p></td></tr><tr><td style="vertical-align:top"><p>Complicated intra-abdominal infections</p></td></tr><tr><td style="vertical-align:top"><p>Peritonitis associated with dialysis in patients on CAPD</p></td></tr><tr><td style="vertical-align:top"><p>Complicated urinary tract infections</p></td><td style="vertical-align:top"><p>1-2 g every 8 h or 12 h</p></td></tr><tr><td style="vertical-align:top"><p>Peri-operative prophylaxis for transurethral resection of prostate (TURP)</p></td><td style="vertical-align:top"><p>1 g at induction of anaesthesia, and a second dose at catheter removal</p></td></tr><tr><td style="vertical-align:top"><p>Chronic suppurative otitis media</p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p><p>1 g to 2 g every 8 h</p></td></tr><tr><td style="vertical-align:top"><p>Malignant otitis externa</p></td></tr><tr><td style="vertical-align:top"><p><em>Continuous infusion</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Infection</p></td><td style="vertical-align:top"><p>Dose to be administered</p></td></tr><tr><td style="vertical-align:top"><p>Febrile neutropenia</p></td><td rowspan="9" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Loading dose of 2 g followed by a continuous infusion of 4 to 6 g every 24 h<sup>1</sup></p><p>The infusion of any unit of dissolved drug shall last no longer than 9h (see section 6.3).</p><p>&nbsp;</p><p>Therefore, following reconstitution, the unit dose in the infusion fluid should be administered within 9 h, for example for 8 g per day: 2 g loading dose followed by 2 g continuous infusion every 8 h.</p></td></tr><tr><td style="vertical-align:top"><p>Nosocomial pneumonia</p></td></tr><tr><td style="vertical-align:top"><p>Broncho-pulmonary infections in cystic fibrosis</p></td></tr><tr><td style="vertical-align:top"><p>Bacterial meningitis</p></td></tr><tr><td style="vertical-align:top"><p>Bacteraemia*</p></td></tr><tr><td style="vertical-align:top"><p>Bone and joint infections</p></td></tr><tr><td style="vertical-align:top"><p>Complicated skin and soft tissue infections</p></td></tr><tr><td style="vertical-align:top"><p>Complicated intra-abdominal infections</p></td></tr><tr><td style="vertical-align:top"><p>Peritonitis associated with dialysis in patients on CAPD</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><sup>1</sup>In adults with normal renal function 9 g/day has been used without adverse effects. *When associated with, or suspected to be associated with, any of the infections listed in 4.1.</p></td></tr></tbody></table><p><u>Table 2: Children &lt; 40 kg</u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Infants and toddlers</p><p>&gt;2 months and</p><p>children &lt;40 kg</p></td><td style="vertical-align:top"><p>Infection</p></td><td style="vertical-align:top"><p>Usual dose</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Intermittent Administration</em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Complicated urinary tract infections</p></td><td rowspan="3" style="vertical-align:top"><p>100-150 mg/kg/day in three divided doses, maximum 6 g/day</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Chronic suppurative otitis media</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Malignant otitis externa</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Neutropenic children</p></td><td rowspan="4" style="vertical-align:top"><p>150 mg/kg/day in three divided doses, maximum 6 g/day</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Broncho-pulmonary infections in cystic fibrosis</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Bacterial meningitis</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Bacteraemia*</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Bone and joint infections</p></td><td rowspan="4" style="vertical-align:top"><p>100 &ndash; 150 mg/kg/day in three divided doses, maximum 6 g/day</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Complicated skin and soft tissue infections</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Complicated intra- abdominal infections</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Peritonitis associated with dialysis in patients on CAPD</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Continuous Infusion</em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Febrile neutropenia</p></td><td style="vertical-align:top"><p>Loading dose of 60-100 mg/kg followed by a continuous infusion 100-200</p><p>mg/kg/day, maximum 6 g/day</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Nosocomial pneumonia</p></td><td rowspan="8" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Broncho-pulmonary infections in cystic fibrosis</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Bacterial meningitis</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Bacteraemia*</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Bone and joint infections</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Complicated skin and soft tissue infections</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Complicated intra- abdominal infections</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Peritonitis associated with dialysis in patients on CAPD</p></td></tr><tr><td style="vertical-align:top"><p>Neonates and infants</p><p>&le; 2 months</p></td><td style="vertical-align:top"><p>Infection</p></td><td style="vertical-align:top"><p>Usual dose</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Intermittent Administration</em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Most infections</p></td><td style="vertical-align:top"><p>25-60 mg/kg/day in two divided doses<sup>1</sup></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>1</sup>In neonates and infants &le; 2 months, the serum half life of ceftazidime can be three to four times that in adults.</p><p>*Where associated with, or suspected to be associated with, any of the infections listed in section 4.1.</p></td></tr></tbody></table><p><u>Paediatric population</u><br />The safety and efficacy of ceftazidime administered as continuous infusion to neonates and infants &le; 2 months has not been established.</p><p><u>Elderly</u><br />In view of the age related reduced clearance of ceftazidime in elderly patients, the daily dose should not normally exceed 3 g in those over 80 years of age.</p><p><u>Hepatic impairment</u><br />Available data do not indicate the need for dose adjustment in mild or moderate liver function impairment. There are no study data in patients with severe hepatic impairment (see also section 5.2). Close clinical monitoring for safety and efficacy is advised.</p><p><u>Renal impairment</u><br />Ceftazidime is excreted unchanged by the kidneys. Therefore, in patients with impaired renal function, the dosage should be reduced (see also section 4.4).</p><p>An initial loading dose of 1 g should be given. Maintenance doses should be based on creatinine clearance:</p><p><u>Table 3: Recommended maintenance doses of Forta-Z in renal impairment &ndash;</u> <u>intermittent infusion</u><br /><em>Adults and children &ge; 40 kg</em></p><table border="1" cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>Creatinine clearance</p><p>ml/min</p></td><td style="vertical-align:top"><p>Approx. serum creatinine</p><p>&micro;mol/l(mg/dl)</p></td><td style="vertical-align:top"><p>Recommended</p><p>unit dose of Forta-Z (g)</p></td><td style="vertical-align:top"><p>Frequency of dosing (hourly)</p></td></tr><tr><td style="vertical-align:top"><p>50-31</p></td><td style="vertical-align:top"><p>150-200</p><p>(1.7-2.3)</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>12</p></td></tr><tr><td style="vertical-align:top"><p>30-16</p></td><td style="vertical-align:top"><p>200-350</p><p>(2.3-4.0)</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>24</p></td></tr><tr><td style="vertical-align:top"><p>15-6</p></td><td style="vertical-align:top"><p>350-500</p><p>(4.0-5.6)</p></td><td style="vertical-align:top"><p>0.5</p></td><td style="vertical-align:top"><p>24</p></td></tr><tr><td style="vertical-align:top"><p>&lt;5</p></td><td style="vertical-align:top"><p>&gt;500</p><p>(&gt;5.6)</p></td><td style="vertical-align:top"><p>0.5</p></td><td style="vertical-align:top"><p>48</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>In patients with severe infections the unit dose should be increased by 50% or the dosing frequency increased. In children the creatinine clearance should be adjusted for body surface area or lean body mass.</p><p><em>Children &lt; 40 kg</em></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Creatinine clearance</p><p>(ml/min)**</p></td><td style="vertical-align:top"><p>Approx. serum creatinine*</p><p>&micro;mol/l (mg/dl)</p></td><td style="vertical-align:top"><p>Recommended individual dose mg/kg body weight</p></td><td style="vertical-align:top"><p>Frequency of dosing (hourly)</p></td></tr><tr><td style="vertical-align:top"><p>50-31</p></td><td style="vertical-align:top"><p>150-200</p><p>(1.7-2.3)</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>12</p></td></tr><tr><td style="vertical-align:top"><p>30-16</p></td><td style="vertical-align:top"><p>200-350</p><p>(2.3-4.0)</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>24</p></td></tr><tr><td style="vertical-align:top"><p>15-6</p></td><td style="vertical-align:top"><p>350-500</p><p>(4.0-5.6)</p></td><td style="vertical-align:top"><p>12.5</p></td><td style="vertical-align:top"><p>24</p></td></tr><tr><td style="vertical-align:top"><p>&lt;5</p></td><td style="vertical-align:top"><p>&gt;500</p><p>(&gt;5.6)</p></td><td style="vertical-align:top"><p>12.5</p></td><td style="vertical-align:top"><p>48</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>* The serum creatinine values are guideline values that may not indicate exactly the same degree of reduction for all patients with reduced renal function.</p><p>** Estimated based on body surface area, or measured.</p></td></tr></tbody></table><p>Close clinical monitoring for safety and efficacy is advised.</p><p><u>Table 4: Recommended maintenance doses of Forta-Z in renal impairment &ndash;</u> <u>continuous infusion</u><br /><em>Adults and children </em>&ge; <em>40 kg</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Creatinine clearance (ml/min)</p></td><td style="vertical-align:top"><p>Approx. Serum creatinine &micro;mol/l (mg/dl)</p></td><td style="vertical-align:top"><p>Frequency of dosing (hourly)</p></td></tr><tr><td style="vertical-align:top"><p>50-31</p></td><td style="vertical-align:top"><p>150-200</p></td><td style="vertical-align:top"><p>Loading dose of 2 g</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(1.7-2.3)</p></td><td style="vertical-align:top"><p>followed by 1 g to 3 g /24 hours</p></td></tr><tr><td style="vertical-align:top"><p>30-16</p></td><td style="vertical-align:top"><p>200-350</p></td><td style="vertical-align:top"><p>Loading dose of 2 g</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(2.3-4.0)</p></td><td style="vertical-align:top"><p>followed by 1 g /24 hours</p></td></tr><tr><td style="vertical-align:top"><p>&le; 15</p></td><td style="vertical-align:top"><p>&gt; 350</p><p>(&gt;4.0)</p></td><td style="vertical-align:top"><p>Not evaluated</p></td></tr></tbody></table><p>Caution is advised in dose selection. Close clinical monitoring for safety and efficacy is advised.</p><p><em>Children &lt; 40 kg</em><br />The safety and effectiveness of ceftazidime administered as continuous infusion in renally impaired children &lt; 40 kg has not been established, Close clinical monitoring for safety and efficacy is advised.</p><p>If continuous infusion is used in children with renal impairment, the creatinine clearance should be adjusted for body surface area or lean body mass.</p><p><u>&nbsp;Haemodialysis</u><br />The serum half-life during haemodialysis ranges from 3 to 5 h.</p><p>&nbsp;Following each haemodialysis period, the maintenance dose of ceftazidime recommended in tables 3 &amp; 4 should be repeated.</p><p><u>Peritoneal dialysis</u><br />&nbsp;Ceftazidime may be used in peritoneal dialysis and continuous ambulatory peritoneal dialysis (CAPD).</p><p>In addition to intravenous use, ceftazidime can be incorporated into the dialysis fluid (usually 125 to 250mg for 2 litres of dialysis solution).</p><p>&nbsp;For patients in renal failure on continuous arterio-venous haemodialysis or high-flux haemofiltration in intensive therapy units: 1 g daily either as a single dose or in divided doses. For low-flux haemofiltration, follow the dose recommended under renal impairment.</p><p>&nbsp;For patients on veno-venous haemofiltration and veno-venous haemodialysis, follow the dosage recommendations in tables 5 &amp; 6 below.</p><p><u>Table 5: Continuous veno-venous haemofiltration dose guidelines</u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Residual</p></td><td colspan="4" style="vertical-align:top"><p>Maintenance dose (mg) for an ultrafiltration rate (ml/min) of<sup>1</sup>:</p></td></tr><tr><td style="vertical-align:top"><p>renal function</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>(creatinine</p><p>clearance</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>16.7</p></td><td style="vertical-align:top"><p>33.3</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p>ml/min)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>250</p></td><td style="vertical-align:top"><p>250</p></td><td style="vertical-align:top"><p>500</p></td><td style="vertical-align:top"><p>500</p></td></tr><tr><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>250</p></td><td style="vertical-align:top"><p>250</p></td><td style="vertical-align:top"><p>500</p></td><td style="vertical-align:top"><p>500</p></td></tr><tr><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>250</p></td><td style="vertical-align:top"><p>500</p></td><td style="vertical-align:top"><p>500</p></td><td style="vertical-align:top"><p>750</p></td></tr><tr><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>250</p></td><td style="vertical-align:top"><p>500</p></td><td style="vertical-align:top"><p>500</p></td><td style="vertical-align:top"><p>750</p></td></tr><tr><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>500</p></td><td style="vertical-align:top"><p>500</p></td><td style="vertical-align:top"><p>500</p></td><td style="vertical-align:top"><p>750</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>1</sup> Maintenance dose to be administered every 12 h.</p></td></tr></tbody></table><p><u>Table 6: Continuous veno-venous haemodialysis dose guidelines</u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="4" style="vertical-align:top"><p><u>Residual</u> <u>renal</u> <u>function</u> <u>(creatinine</u> <u>clearance</u> <u>in ml/min)</u></p></td><td colspan="6" style="vertical-align:top"><p>Maintenance dose (mg) for a dialysate in flow rate of <sup>1</sup><sub>:</sub></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>1.0 litre/h</u></p></td><td colspan="3" style="vertical-align:top"><p><u>2.0 litre/h</u></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Ultrafiltration rate (litre/h)</u></p></td><td colspan="3" style="vertical-align:top"><p><u>Ultrafiltration rate (litre/h)</u></p></td></tr><tr><td style="vertical-align:top"><p><u>0.5</u></p></td><td style="vertical-align:top"><p><u>1.0</u></p></td><td style="vertical-align:top"><p><u>2.0</u></p></td><td style="vertical-align:top"><p><u>0.5</u></p></td><td style="vertical-align:top"><p><u>1.0</u></p></td><td style="vertical-align:top"><p><u>2.0</u></p></td></tr><tr><td style="vertical-align:top"><p><u>0</u></p></td><td style="vertical-align:top"><p><u>500</u></p></td><td style="vertical-align:top"><p><u>500</u></p></td><td style="vertical-align:top"><p><u>500</u></p></td><td style="vertical-align:top"><p><u>500</u></p></td><td style="vertical-align:top"><p><u>500</u></p></td><td style="vertical-align:top"><p><u>750</u></p></td></tr><tr><td style="vertical-align:top"><p><u>5</u></p></td><td style="vertical-align:top"><p><u>500</u></p></td><td style="vertical-align:top"><p><u>500</u></p></td><td style="vertical-align:top"><p><u>750</u></p></td><td style="vertical-align:top"><p><u>500</u></p></td><td style="vertical-align:top"><p><u>500</u></p></td><td style="vertical-align:top"><p><u>750</u></p></td></tr><tr><td style="vertical-align:top"><p><u>10</u></p></td><td style="vertical-align:top"><p><u>500</u></p></td><td style="vertical-align:top"><p><u>500</u></p></td><td style="vertical-align:top"><p><u>750</u></p></td><td style="vertical-align:top"><p><u>500</u></p></td><td style="vertical-align:top"><p><u>750</u></p></td><td style="vertical-align:top"><p><u>1000</u></p></td></tr><tr><td style="vertical-align:top"><p><u>15</u></p></td><td style="vertical-align:top"><p><u>500</u></p></td><td style="vertical-align:top"><p><u>750</u></p></td><td style="vertical-align:top"><p><u>750</u></p></td><td style="vertical-align:top"><p><u>750</u></p></td><td style="vertical-align:top"><p><u>750</u></p></td><td style="vertical-align:top"><p><u>1000</u></p></td></tr><tr><td style="vertical-align:top"><p><u>20</u></p></td><td style="vertical-align:top"><p><u>750</u></p></td><td style="vertical-align:top"><p><u>750</u></p></td><td style="vertical-align:top"><p><u>1000</u></p></td><td style="vertical-align:top"><p><u>750</u></p></td><td style="vertical-align:top"><p><u>750</u></p></td><td style="vertical-align:top"><p><u>1000</u></p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><sup>1</sup>Maintenance dose to be administered every 12 h.</p></td></tr></tbody></table><p><u>Method of administration</u><br />The dose depends on the severity, susceptibility, site and type of infection and on the age and renal function of the patient.</p><p>&nbsp;Forta-Z 1 g should be administered by intravenous injection or infusion, or by deep intramuscular injection. Recommended intramuscular injection sites are the upper outer quadrant of the gluteus maximus or lateral part of the thigh. Forta-Z solutions may be given directly into the vein or introduced into the tubing of a giving set if the patient is receiving parenteral fluids. The standard recommended route of administration is by intravenous intermittent injection or intravenous continuous infusion. Intramuscular administration should only be considered when the intravenous route is not possible or less appropriate for the patient.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to ceftazidime, to any other cephalosporin or to any of the excipients listed in section 6.1.

History of severe hypersensitivity (e.g. anaphylactic reaction) to any other type of beta-lactam antibacterial agent (penicillins, monobactams and carbapenems).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hypersensitivity</u><br />As with all beta-lactam antibacterial agents, serious and occasionally fatal hypersensitivity reactions have been reported. In case of severe hypersensitivity reactions, treatment with ceftazidime must be discontinued immediately and adequate emergency measures must be initiated.</p><p>Before beginning treatment, it should be established whether the patient has a history of severe hypersensitivity reactions to ceftazidime, to other cephalosporins or to any other type of beta-lactam agent. Caution should be used if ceftazidime is given to patients with a history of non-severe hypersensitivity to other beta-lactam agents.</p><p><u>Spectrum of activity</u><br />Ceftazidime has a limited spectrum of antibacterial activity. It is not suitable for use as a single agent for the treatment of some types of infections unless the pathogen is already documented and known to be susceptible or there is a very high suspicion that the most likely pathogen(s) would be suitable for treatment with ceftazidime. This particularly applies when considering the treatment of patients with bacteraemia and when treating bacterial meningitis, skin and soft tissue infections and bone and joint infections. In addition, ceftazidime is susceptible to hydrolysis by several of the extended spectrum beta lactamases (ESBLs). Therefore information on the prevalence of ESBL producing organisms should be taken into account when selecting ceftazidime for treatment.</p><p><u>&nbsp;Pseudomembranous colitis</u><br />Antibacterial agent-associated colitis and pseudo-membranous colitis have been reported with nearly all anti-bacterial agents, including ceftazidime, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of ceftazidime (see section 4.8). Discontinuation of therapy with ceftazidime and the administration of specific treatment for&nbsp;<em>Clostridium difficile&nbsp;</em>should be considered. Medicinal products that inhibit peristalsis should not be given.</p><p><u>Renal function</u><br />Concurrent treatment with high doses of cephalosporins and nephrotoxic medicinal products such as aminoglycosides or potent diuretics (e.g. furosemide) may adversely affect renal function.</p><p>Ceftazidime is eliminated via the kidneys, therefore the dose should be reduced according to the degree of renal impairment. Patients with renal impairment should be closely monitored for both safety and efficacy. Neurological sequelae have occasionally been reported when the dose has not been reduced in patients with renal impairment (see section 4.2 and 4.8).</p><p><u>Overgrowth of non-susceptible organisms</u><br />Prolonged use may result in the overgrowth of non-susceptible organisms (e.g. Enterococci, fungi) which may require interruption of treatment or other appropriate measures. Repeated evaluation of the patient&#39;s condition is essential.</p><p><u>Test and assay interactions</u><br />Ceftazidime does not interfere with enzyme-based tests for glycosuria, but slight interference (false-positive) may occur with copper reduction methods (Benedict&#39;s, Fehling&#39;s, Clinitest).</p><p>Ceftazidime does not interfere in the alkaline picrate assay for creatinine.</p><p>The development of a positive Coombs&#39; test associated with the use of ceftazidime in about 5% of patients may interfere with the cross-matching of blood.</p><p><strong>Forta-Z contains sodium</strong><br />Forta-Z contains sodium. Each vial of Forta-Z 1 g Powder for Solution for Injection/Infusion contains 84.19 mg sodium (main component of cooking/table salt). This is equivalent to 4.21% of the recommended maximum daily dietary intake of sodium for an adult.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interaction studies have only been conducted with a probenecid and furosemide.</p><p>Concurrent use of high doses with nephrotoxic medicinal products may adversely affect renal function (see section 4.4).</p><p>Chloramphenicol is antagonistic&nbsp;<em>in vitro</em>&nbsp;with ceftazidime and other cephalosporins. The clinical relevance of this finding is unknown, but if concurrent administration of ceftazidime with chloramphenicol is proposed, the possibility of antagonism should be considered.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u><br />There are limited amounts of data from the use of ceftazidime in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3).</p><p>Forta-Z should be prescribed to pregnant women only if the benefit outweighs the risk.</p><p><u>Breast-feeding</u><br />Ceftazidime is excreted in human milk in small quantities but at therapeutic doses of ceftazidime no effects on the breast-fed infant are anticipated. Ceftazidime can be used during breast-feeding.</p><p><u>Fertility</u><br />No data are available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. However, undesirable effects may occur (e.g. dizziness), which may influence the ability to drive and use machines (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most common adverse reactions are eosinophilia, thrombocytosis, phlebitis or thrombophlebitis with intravenous administration, diarrhoea, transient increases in hepatic enzymes, maculopapular or urticarial rash, pain and/or inflammation following intramuscular injection and positive Coomb&#39;s test.</p><p>Data from sponsored and unsponsored clinical trials have been used to determine the frequency of common and uncommon undesirable effects. The frequencies assigned to all other undesirable effects were mainly determined using post-marketing data and refer to a reporting rate rather than a true frequency. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. The following convention has been used for the classification of frequency:</p><p>Very common (&ge;1/10)</p><p>Common (&ge;1/100 to &lt;1/10)</p><p>Uncommon (&ge;1/1,000 to &lt;1/100)</p><p>Rare (&ge;1/10,000 to &lt;1/1000)</p><p>Very rare (&lt;1/10,000)</p><p>Unknown (cannot be estimated from the available data)</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Very rare</strong></p></td><td style="vertical-align:top"><p><strong>Unknown</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Candidiasis (including vaginitis and oral thrush)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>Eosinophilia</p><p>Thrombocytosis</p></td><td style="vertical-align:top"><p>Neutropenia</p><p>Leucopenia</p><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Agranulocytosis</p><p>Haemolytic anaemia</p><p>Lymphocytosis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaphylaxis (including bronchospasm and/or hypotension) (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Headache</p><p>Dizziness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Neurological sequelae<sup>1</sup></p><p>Paraesthesia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>Phlebitis or thrombophlebitis with intravenous administration</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>Antibacterial agent-associated diarrhoea and colitis<sup>2</sup>&nbsp;(see section 4.4)</p><p>Abdominal pain</p><p>Nausea</p><p>Vomiting</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Bad taste</p></td></tr><tr><td style="vertical-align:top"><p><strong>Heptobiliary disorders</strong></p></td><td style="vertical-align:top"><p>Transient elevations in one or more hepatic enzymes<sup>3</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Jaundice</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>Maculopapular or urticarial rash</p></td><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Toxic epidermal necrolysis</p><p>Stevens-Johnson syndrome</p><p>Erythema multiforme</p><p>Angioedema</p><p>Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)<sup>4</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Transient elevations of blood urea, blood urea nitrogen and/or serum creatinine</p></td><td style="vertical-align:top"><p>Interstitial nephritis</p><p>Acute renal failure</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>Pain and/or inflammation after intramuscular injection</p></td><td style="vertical-align:top"><p>Fever</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>Positive Coombs&#39; test<sup>5</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><sup>1</sup>There have been reports of neurological sequelae including tremor, myoclonia, convulsions, encephalopathy and coma in patients with renal impairment in whom the dose of ceftazidime has not been appropriately reduced.</p><p><sup>2</sup>Diarrhoea and colitis may be associated with&nbsp;<em>Clostridium difficile</em>&nbsp;and may present as pseudomembranous colitis.</p><p><sup>3</sup>ALT (SGPT), AST (SOGT), LHD, GGT, alkaline phosphatase.</p><p><sup>4</sup>There have been rare reports where DRESS has been associated with ceftazidime.</p><p><sup>5</sup>A positive Coombs test develops in about 5% of patients and may interfere with blood cross matching.</p><p><strong>&nbsp;Reporting of suspected adverse reactions</strong><br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdose can lead to neurological sequelae including encephalopathy, convulsions and coma.</p><p>Symptoms of overdose can occur if the dose is not reduced appropriately in patients with renal impairment (see sections 4.2 and 4.4).</p><p>Serum levels of ceftazidime can be reduced by haemodialysis or peritoneal dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antibacterials for systemic use.</p><p>Third-generation cephalosporins ATC code: J01DD02</p><p><u>Mechanism of action</u><br />Ceftazidime inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death.</p><p><u>PK/PD relationship</u><br />For cephalosporins, the most important pharmacokinetic-pharmacodynamic index correlating with&nbsp;<em>in vivo</em>&nbsp;efficacy has been shown to be the percentage of the dosing interval that the unbound concentration remains above the minimum inhibitory concentration (MIC) of ceftazidime for individual target species (i.e. %T&gt;MIC).</p><p><u>Mechanism of Resistance</u><br />Bacterial resistance to ceftazidime may be due to one or more of the following mechanisms:</p><ul><li>Hydrolysis by beta-lactamases. Ceftazidime may be efficiently hydrolysed by extended-spectrum beta-lactamases (ESBLs), including the SHV family of ESBLs and AmpC enzymes that may be induced or stably derepressed in certain aerobic Gram-negative bacterial species</li><li>Reduced affinity of penicillin-binding proteins for ceftazidime</li><li>Outer membrane impermeability, which restricts access of ceftazidime to penicillin binding proteins in Gram-negative organisms</li><li>Bacterial efflux pumps.</li></ul><p><u>Breakpoints</u><br />Minimum inhibitory concentration (MIC) breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are as follows:</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Organism</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Breakpoints (mg/L)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>S</p></td><td style="vertical-align:top"><p>I</p></td><td style="vertical-align:top"><p>R</p></td></tr><tr><td style="vertical-align:top"><p>Enterobacteriaceae</p></td><td style="vertical-align:top"><p>&le;1</p></td><td style="vertical-align:top"><p>2-4</p></td><td style="vertical-align:top"><p>&gt;4</p></td></tr><tr><td style="vertical-align:top"><p><em>Pseudomonas aeruginosa</em></p></td><td style="vertical-align:top"><p>&le;8<sup>1</sup></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>&gt;8</p></td></tr><tr><td style="vertical-align:top"><p><em>Non-species related breakpoints<sup>2</sup></em></p></td><td style="vertical-align:top"><p>&le;4</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>&gt;8</p></td></tr></tbody></table><p>S=Susceptible, I=Intermediate, R=Resistant</p><p><sup>1</sup>The breakpoints relate to high dose therapy (2 g x 3).</p><p><sup>2</sup>Non-species related breakpoints have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific species. They are for use only for species not mentioned in the table or footnotes.</p><p><em><u>Microbiological Susceptibility</u></em><br />The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of ceftazidime in at least some types of infections is questionable.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Commonly Susceptible Species</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-positive aerobes:</u></p><p><em>Streptococcus pyogenes</em></p><p><em>Streptococcus agalactiae</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-negative aerobes:</u></p><p><em>Citrobacter koseri</em></p><p><em>Haemophilus influenzae</em></p><p><em>Moraxella catarrhalis</em></p><p><em>Neisseria meningitidis</em></p><p><em>Pasteurella multocida</em></p><p><em>Proteus mirabilis</em></p><p><em>Proteus spp&nbsp;</em>(other)</p><p><em>Providencia</em>&nbsp;spp.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Species for which acquired resistance may be a problem</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-negative aerobes:</u></p><p><em>Acinetobacter baumannii<sup>+</sup></em></p><p><em>Burkholderia cepacia</em></p><p><em>Citrobacter freundii</em></p><p><em>Enterobacter aerogenes</em></p><p><em>Enterobacter cloacae</em></p><p><em>Escherichia coli</em></p><p><em>Klebsiella pneumoniae</em></p><p><em>Klebsiella spp (other)</em></p><p><em>Pseudomonas aeruginosa</em></p><p><em>Serratia spp</em></p><p><em>Morganella morganii</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-positive aerobes:</u></p><p><em>Staphylococcus aureus&pound;</em></p><p><em>Streptococcus pneumoniae<sup>&pound;&pound;</sup></em></p><p><em>Viridans group streptococcus</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-positive anaerobes:</u></p><p><em>Clostridium perfringens</em></p><p><em>Peptostreptococcus spp.</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-negative anaerobes</u></p><p><em>Fusobacterium spp.</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>Inherently resistant organisms</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-positive aerobes:</u></p><p>Enterococcus spp including<em>&nbsp;Enterococcus faecalis&nbsp;</em>and&nbsp;<em>Enterococcus faecium Listeria spp.</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-positive anaerobes:</u></p><p><em>Clostridium difficile</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-negative anaerobes:</u></p><p><em>Bacteroides</em>&nbsp;spp. (many strains of&nbsp;<em>Bacteroides fragilis</em>&nbsp;are resistant).</p></td></tr><tr><td style="vertical-align:top"><p><u>Others:</u></p><p><em>Chlamydia&nbsp;</em>spp</p><p><em>Mycoplasma</em>&nbsp;spp</p><p><em>Legionella</em>&nbsp;spp</p></td></tr><tr><td style="vertical-align:top"><p><sup>&pound;</sup>S.<em>aureus</em>&nbsp;that is methicillin susceptible are considered to have inherent low susceptibility to ceftazidime.All methicillin-resistance&nbsp;<em>S. Aureus</em>&nbsp;are resistant to ceftazidime.</p><p><sup>&pound;&pound;</sup>S.pneumoniae that demonstrate intermediate susceptibility or are resistant to penicillin can be expected to demonstrate at least reduced susceptibility to ceftazidime.</p><p>+High rates of resistance have been observed in one or more areas/countries/regions within the EU.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u><br />After intramuscular administration of 500 mg and 1 g of ceftazidime, peak plasma levels of 18 and 37 mg/l, respectively are achieved rapidly. Five minutes after intravenous bolus injection of 500 mg, 1 g or 2 g, plasma levels are 46, 87 and 170mg/l, respectively. The kinetics of ceftazidime are linear within the single dose range of 0.5 to 2 g following intravenous or intramuscular dosing.</p><p><u>Distribution</u><br />The serum protein binding of ceftazidime is low at about 10%. Concentrations in excess of the MIC for common pathogens can be achieved in tissues such as bone, heart, bile, sputum, aqueous humour, synovial, pleural and peritoneal fluids. Ceftazidime crosses the placenta readily, and is excreted in the breast milk. Penetration of the intact blood-brain barrier is poor, resulting in low levels of ceftazidime in the CSF in the absence of inflammation. However, concentrations of 4 to 20 mg/l or more are achieved in the CSF when the meninges are inflamed.</p><p><u>Biotransformation</u><br />Ceftazidime is not metabolised.</p><p><u>Elimination</u><br />After parenteral administration plasma levels decrease with a half-life of about 2 h. Ceftazidime is excreted unchanged into the urine by glomerular filtration; approximately 80 to 90 % of the dose is recovered in the urine within 24 h. Less than 1 % is excreted via the bile.</p><p><u>Special patient populations</u><br /><em>Renal impairment</em><br />Elimination of ceftazidime is decreased in patients with impaired renal function and the dose should be reduced (see section 4.2).</p><p><em>&nbsp;Hepatic impairment</em><br />The presence of mild to moderate hepatic dysfunction had no effect on the pharmacokinetics of ceftazidime in individuals administered 2 g intravenously every 8 hours for 5 days, provided renal function was not impaired (see section 4.2).</p><p><em>&nbsp;Elderly</em><br />The reduced clearance observed in elderly patients was primarily due to age-related decrease in renal clearance of ceftazidime. The mean elimination half-life ranged from 3.5 to 4 hours following single or 7 days repeat BID dosing of 2 g IV bolus injections in elderly patients 80 years or older.</p><p><em>Paediatric population</em><br />The half-life of ceftazidime is prolonged in preterm and term neonates by 4.5 to 7.5 hours after doses of 25 to 30 mg/kg. However, by the age of 2 months the half-life is within the range for adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on studies of safety pharmacology, repeat dose toxicity, genotoxicity, toxicity to reproduction. Carcinogenicity studies have not been performed with ceftazidime.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp; Sodium carbonate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ceftazidime is less stable in sodium bicarbonate injection than in other intravenous fluids. It is not recommended as a diluent.</p><p>Ceftazidime and aminoglycosides should not be mixed in the same giving set or syringe.</p><p>Precipitation has been reported with vancomycin added to ceftazidime in solution. Therefore, it would be prudent to flush giving sets and intravenous lines between administration of these two agents.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.

After reconstitution:
Chemical and physical in-use stability has been demonstrated for 24 hours at 2-8°C in water for injection or compatible fluids listed below.

From a microbiological point of view, the reconstituted solution should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless reconstitution has taken place in controlled and validated aseptic conditions.

After dilution:
Chemical and physical in-use stability has been demonstrated for 24 hours at 2-8°C in compatible fluids listed below.

From a microbiological point of view, the reconstituted and diluted solution should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless reconstitution has taken place in controlled and validated aseptic conditions.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Store in the original package to protect from light.</p><p>For storage conditions after reconstitution see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>50 ml type II clear moulded glass vials sealed with bromobutyl rubber stoppers and aluminum caps.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>After reconstitution:</strong><br />Chemical and physical in-use stability has been demonstrated for 24 hours at 2-8&deg;C in water for injection or compatible fluids listed below.</p><p>From a microbiological point of view, the reconstituted solution should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8&deg;C, unless reconstitution has taken place in controlled and validated aseptic conditions.</p><p><strong>After dilution:</strong><br />Chemical and physical in-use stability has been demonstrated for 24 hours at 2-8&deg;C in compatible fluids listed below.</p><p>From a microbiological point of view, the reconstituted and diluted solution should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8&deg;C, unless reconstitution has taken place in controlled and validated aseptic conditions.</p><p><strong>Special precautions for disposal and other handling</strong><br />As the product dissolves, carbon dioxide is released. Small bubbles of carbon dioxide in the constituted solution may be ignored.</p><p><strong>Instructions for constitution</strong><br />See Table 7 and Table 8 for addition volumes and solution concentrations, which may be useful when fractional doses are required.</p><p>Table 7: Powder for Solution for Injection</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Presentation</p></td><td style="vertical-align:top"><p>Amount of diluent to be added (ml)</p></td><td style="vertical-align:top"><p>Approximate concentration (mg/ml)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>1 g</p></td></tr><tr><td style="vertical-align:top"><p>Intramuscular</p><p>Intravenous bolus</p></td><td style="vertical-align:top"><p>3 ml</p><p>10 ml</p></td><td style="vertical-align:top"><p>260</p><p>90</p></td></tr></tbody></table><p>Note:</p><ul><li>The resulting volume of the solution of ceftazidime in reconstitution medium is increased due to the displacement factor of the drug product resulting in the listed concentrations in mg/ml presented in the above table.</li></ul><p>Table 8: Powder for Solution for Infusion</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Presentation</p></td><td style="vertical-align:top"><p>Amount of diluent to be added (ml)</p></td><td style="vertical-align:top"><p>Approximate concentration (mg/ml)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>1 g</p></td></tr><tr><td style="vertical-align:top"><p>Intravenous infusion</p></td><td style="vertical-align:top"><p>50 ml*</p></td><td style="vertical-align:top"><p>20</p></td></tr></tbody></table><p>&nbsp;* Addition should be in two stages.</p><p>Note:</p><ul><li>The resulting volume of the solution of ceftazidime in reconstitution medium is increased due to the displacement factor of the drug product resulting in the listed concentrations in mg/ml presented in the above table.</li></ul><p>Solutions range in colour from light yellow to amber depending on concentration, diluent and storage conditions used. Within the stated recommendations, product potency is not adversely affected by such colour variations.</p><p>Ceftazidime at concentrations between 1 mg/ml and 40 mg/ml is compatible with:</p><ul><li>9 mg/ml (0.9%) Sodium chloride solution for injection</li><li>M/6 Sodium lactate injection</li><li>Compound sodium lactate injection (Hartmann&rsquo;s solution)</li><li>5% Dextrose injection</li><li>0.225% Sodium chloride and 5% dextrose injection</li><li>0.45% Sodium chloride and 5% dextrose injection</li><li>0.9% Sodium chloride and 5% dextrose injection</li><li>0.18% Sodium chloride and 4% dextrose injection</li><li>10% Dextrose Injection</li></ul><p>Ceftazidime at concentrations between 0.05 mg/ml and 0.25 mg/ml is compatible with Intra-peritoneal dialysis fluid (Lactate).</p><p>Ceftazidime at concentrations detailed in Table 7 may be constituted for intramuscular use with 0.5% or 1% lidocaine hydrochloride injection.</p><p><strong>Preparation of solution for bolus injection:</strong></p><ol><li>Insert the syringe needle through the vial closure and inject the recommended volume of diluent. Remove the syringe needle.</li><li>Shake to dissolve: carbon dioxide is released and a clear solution will be obtained in about 1 to 2 minutes.</li><li>Invert the vial. With the syringe plunger fully depressed, insert the needle through the vial closure and withdraw the total volume of solution into the syringe (the pressure in the vial may aid withdrawal). Ensure that the needle remains within the solution and does not enter the head space. The withdrawn solution may contain small bubbles of carbon dioxide; they may be disregarded.</li></ol><p>These solutions may be given directly into the vein or introduced into the tubing of a giving set if the patient is receiving parenteral fluids. Ceftazidime is compatible with the intravenous fluids listed above.</p><p><strong>Preparation of solutions for IV infusion from ceftazidime injection in standard vial presentation (mini-bag or burette-type set):</strong><br />Prepare using a total of 50 ml of compatible diluents (listed above), added in two stages as below.</p><ol><li>Introduce the syringe needle through the vial closure and inject 10 ml of diluent for the 1 g vial.</li><li>Withdraw the needle and shake the vial to give a clear solution.</li><li>Do not insert a gas relief needle until the product has dissolved. Insert a gas relief needle through the vial closure to relieve the internal pressure.</li><li>Transfer the reconstituted solution to final delivery vehicle (e.g. mini-bag or burette-type set) making up a total volume of at least 50 ml, and administer by intravenous infusion over 15 to 30 min.</li></ol><p>Note: To preserve product sterility, it is important that the gas relief needle is not inserted through the vial closure before the product has dissolved.</p><p>Any residual antibiotic solution should be discarded.</p><p>For single use only.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries 
Al-Kharj Road 
P.O. BOX 106229 
Riyadh 11666, Saudi Arabia 
Tel: + (966-11) 4980170 
Fax: + (966-11) 4980187 
e-mail: SAPV@hikma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                07 February 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>